stockrow
Friday 6 November 2026
Export BDX’s income statement to Excel — free account
Becton, Dickinson and Company
BDX Healthcare Medical Instruments & Supplies
Becton, Dickinson and Company’s revenue for fiscal 2025 (year ended September 2025) was $21.8 billion, up 8.24% from fiscal 2024.
- Revenue
- −9.55%
- EPS
- −31.5%
- Free cash flow
- −31.6%
- Total debt
- −22.9%
Quarter to June 2026, against a year earlier
212.96
3.77
+1.80%
Follow BDX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
6.54% | 6.96% | 4.61% | 3.77% | |
Piotroski F-Score |
7 | 7 | 7 | 7 | |
| 2.98% | 3.21% | 2.16% | 1.78% | ||
ROIC |
3.82% | 4.06% | 3.94% | 3.89% | |
Return on Tangible Assets |
22.91% | 23.74% | 20.37% | 19.53% | |
Average Days of Receivables |
40.04 | 41.75 | 37.67 | 41.40 | |
Free Cash Flow per Share |
9.28 | 9.21 | 12.45 | 11.66 | |
Free Cash Flow |
2,670.00 | 2,631.00 | 3,495.00 | 3,203.00 | |
Capital Expenditures |
(760.00) | (763.00) | (774.00) | (753.00) | |
| Other line items | |||||
Cash ROIC |
6.10% | 6.09% | 8.77% | 8.26% | |
Accounts Receivable Turnover |
8.05 | 8.52 | 8.16 | 7.85 | |
Accounts Payable Turnover |
2.98 | 1.89 | 1.96 | 1.92 | |
Inventory Turnover |
3.41 | 2.98 | 3.32 | 3.29 | |
Average Days of Payables |
187.05 | 189.49 | 184.11 | 186.67 | |
Days of Inventory on Hand |
96.47 | 126.11 | 104.16 | 101.36 | |
Tax Rate |
(0.11) | (0.11) | (0.14) | (0.13) | |
Research and Development Expense of Revenue |
5.79% | 5.60% | 5.83% | 6.11% | |
Selling, General and Administrative Expense of Revenue |
24.17% | 24.42% | 25.50% | 26.62% | |
Share Based Compensation of Revenue |
1.18% | 1.18% | 1.29% | 1.36% | |
Interest Coverage |
4.21 | 4.38 | 3.91 | 3.91 | |
Operating CF/Net income |
2.04 | 1.93 | 3.75 | 4.20 | |
Depreciation/Fixed assets |
0.39 | 0.35 | 0.41 | 0.40 | |
Capex/Depreciation |
(0.31) | (0.31) | (0.31) | (0.31) | |
Revenue per Share |
75.93 | 76.77 | 76.13 | 75.84 | |
Operating CF per Share |
11.92 | 11.88 | 15.21 | 14.40 | |
Capex per Share |
(2.64) | (2.67) | (2.76) | (2.74) | |
Capex to Sales |
0.03 | 0.03 | 0.04 | 0.04 |
Columns are period end dates · fundamentals updated 26 Oct 2026